Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert E. George is Director at Moleculin Biotech. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 19, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
Nov 17, 20264,000disclosed Nov 19
DetailsOfficial recordRobert E. George bought shares on the open market in 2017 and 2023, and has not bought since 2023.
Robert E. George reported 2 open-market purchases and 0 sales since 2017; purchases in 2 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $10K1×1 trade | — |
| 2017 | $9401×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Robert E. George bought shares on the open market in 2017 and 2023, and has not bought since 2023.
In SEC filings since 2017: the latest open-market purchase is from 2023; no open-market sale is on record.
Moleculin Biotech (MBRX), from 2017 to 2023: 2 purchases and 0 sales.
Robert E. George reported 2 open-market purchases and 0 sales here, 2017 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.